Biology Atlas

Map / Scenarios

scenario · intermediate · partly written

A rare disease: from phenotype to a place to intervene

Situation

A family has a disease with a clear phenotype and no known gene. A clinical team can sequence the patient and relatives. Nothing here describes any real person: it is a generic starting point. 1

Reported, not yet replicated

Ask

You know the phenotype and little else. What do you do next?

Options

Exome sequencing with phenotype-driven ranking

Sequence the coding regions, encode the phenotype as standard terms and rank variants by how well the gene fits the phenotype. 21

Cost. Not found in an opened source.

Tells you. A short ranked list: in 134 retinal exomes the phenotype-aware tool put the causal variant first in 74% of cases against 3% from variants alone (abstract level); in 371 children with developmental delay the diagnostic yield was 27%.

Does not tell you. Anything outside coding regions; and 11.3% of the same children carried variants of uncertain significance rather than a diagnosis.

See: Whole-exome sequencing, a record that is not published here

Reported, not yet replicated

Whole-genome sequencing

Read the whole genome, so noncoding and structural variants are in scope. 34

Cost. About 221 USD per 30x genome at one core facility (undated page; excludes analysis and storage).

Tells you. A wider list of variants, including regions a capture never targets.

Does not tell you. Variants in repeats and near-identical gene copies, which short reads place ambiguously; a benchmark that covers 92.2% of autosomal bases still excludes the rest.

See: Whole-genome sequencing, a record that is not published here

Reported, not yet replicated

Classify the candidate variant under the ACMG/AMP standard

Weigh population frequency, computation, function, segregation and de novo evidence; if conflicting or too little, the variant stays of uncertain significance. 5

Cost. Analyst time; not costed here.

Tells you. Whether the variant meets the evidence for pathogenic, likely pathogenic or neither.

Does not tell you. Whether the gene is a drug target, or the direction a drug should push.

See: a record that is not published here

Established

What really happened

PCSK9: a Mendelian gene to a lipid-lowering target

Mutations in PCSK9 were reported in 2003 in families with autosomal dominant hypercholesterolaemia (abstract level). In 2005 nonsense variants in PCSK9 were reported in 128 people with low LDL cholesterol, about 40% lower (abstract level). A prospective review lists PCSK9 as a worked example of gain-of-function and loss-of-function variants pointing to a drug target. The date of approval of the PCSK9 antibody drug alirocumab could not be opened by the chain and is not given. This is a family-and-population case of a gene with a lipid phenotype, not a single-patient diagnosis; it shows the rare-disease route's pattern, in which a drug compensates a loss. 678

Reported, not yet replicated

Still open here

Linked from

Sources

  1. Bowling, K., Thompson, M., Amaral, M., et al.. Genomic diagnosis for children with intellectual disability and/or developmental delay. Genome Medicine (2017). paper; opened 2026-11-17 all records citing this
  2. Cipriani V, Pontikos N, Arno G, et al.. An Improved Phenotype-Driven Tool for Rare Mendelian Variant Prioritization: Benchmarking Exomiser on Real Patient Whole-Exome Data. Genes (Basel) (2020). paper; opened 2026-11-17 all records citing this
  3. University of Minnesota Genomics Center: human whole-genome sequencing. University of Minnesota (2026). organisation-page, not peer reviewed; opened 2026-11-17 all records citing this
  4. Wagner J, Olson ND, Harris L, et al.. Benchmarking challenging small variants with linked and long reads. Cell Genom (2022). paper; opened 2026-11-17 all records citing this
  5. Richards, S., Aziz, N., Bale, S., et al.. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine (2015). paper; opened 2026-11-17 all records citing this
  6. Abifadel, M., Varret, M., Rabès, J., et al.. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genetics (2003). paper; opened 2026-11-17 all records citing this
  7. Cohen, J., Pertsemlidis, A., Kotowski, I., et al.. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nature Genetics (2005). paper; opened 2026-11-17 all records citing this
  8. Trajanoska, K., et al.. From target discovery to clinical drug development with human genetics. Nature (2023). paper; opened 2026-11-17 all records citing this
History of this record (2)

This record has been changed 2 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Status
partly written
Last updated
2026-11-17
Record
content/scenarios/rare-disease-from-phenotype-to-modality.json